Biotech firms lobby states to limit generic drug competition

The following is an excerpt.

In statehouses around the country, some of the nation’s biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.

View the original article here: Biotech Firms, Billions at Risk, Lobby States to Limit Generics

Related on the SLP

Industry awaits FDA ruling on ‘generic’ versions of biologically derived drugs Crippling costs blunt potential of drugs harvested from living cells

Viewpoint: Is corporate embrace of regenerative agriculture greenwashing?

Trump says he’ll require drugmakers to end multiple vaccine doses, reviving discredited autism claims

Slowdown AI development? China acknowledges serious risks but sees warnings as U.S. ploy to control the technology

Additional Resources:

• “’The Signal and the Noise’ in pharmacogenomics,” The Genetic Literacy Project